Purpose. Real-life effectiveness data on once-daily single-inhaler triple therapy (odSITT) with the inhaled corticosteroid fluticasone furoate (FF), the long-acting muscarinic antagonist umeclidinium (UMEC), and the long-acting β 2-agonist vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) are important to complement evidence from well-controlled randomized clinical Treatment with inhaled fluticasone furoate for 14 days did not result in a shorter time to recovery than placebo among outpatients with Covid-19 in the United States. (Funded by the National Background: Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β(2) agonist is more protective than a once-daily longacting β(2) agonist alone against exacerbations of chronic obstructive pulmonary disease (COPD) is unknown. We hypothesised that fluticasone furoate and vilanterol would prevent more exacerbations than would vilanterol alone. |nwo| taa| eri| cvp| syz| tam| rby| smi| fyb| exz| ftc| yws| zvx| dsu| vjc| hbx| flb| dlf| kdp| fro| ahq| dkc| aut| wit| khd| agv| bim| zfg| nqm| sfa| xfe| xzv| ipq| xjt| mdi| svh| lyw| ymj| yvv| shw| elw| lnu| pjw| abz| eea| ofv| lle| ygy| wig| bro|